

Bryan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4832625/publications.pdf>

Version: 2024-02-01

55
papers

2,399
citations

304743

22
h-index

223800

46
g-index

55
all docs

55
docs citations

55
times ranked

3576
citing authors

#	ARTICLE	IF	CITATIONS
1	Commentary: Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment. <i>Neurosurgery</i> , 2021, 89, E68-E69.	1.1	1
2	Neurophysiologic Mapping of Thalamocortical Tract in Asleep Craniotomies: Promising Results From an Early Experience. <i>Operative Neurosurgery</i> , 2021, 20, 219-225.	0.8	5
3	Commentary: The Glioma-Network Interface: A Review of the Relationship Between Glioma Molecular Subtype and Intratumoral Function. <i>Neurosurgery</i> , 2021, 88, E273-E274.	1.1	0
4	Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR-T-Cells for Myeloid Leukemia. <i>Blood</i> , 2021, 138, 405-405.	1.4	1
5	A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. <i>Molecular Therapy</i> , 2020, 28, 2577-2592.	8.2	58
6	Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1147-1158.	3.1	8
7	IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. <i>Oncolmmunology</i> , 2020, 9, 1806662.	4.6	26
8	Survival After Surgery for Renal Cell Carcinoma Metastatic to the Spine: Impact of Modern Systemic Therapies on Outcomes. <i>Neurosurgery</i> , 2020, 87, 1174-1180.	1.1	10
9	A Common Rule for Resection of Glioblastoma in the Molecular Era. <i>JAMA Oncology</i> , 2020, 6, 503.	7.1	3
10	Receptor tyrosine kinase gene amplification is predictive of intraoperative seizures during glioma resection with functional mapping. <i>Journal of Neurosurgery</i> , 2020, 132, 1017-1023.	1.6	5
11	CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. <i>Nature Biotechnology</i> , 2019, 37, 1049-1058.	17.5	347
12	A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition. <i>Oncolmmunology</i> , 2019, 8, e1678921.	4.6	18
13	Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. <i>Blood Advances</i> , 2019, 3, 3248-3260.	5.2	76
14	CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. , 2019, 7, 304.		181
15	Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. <i>Clinical Cancer Research</i> , 2019, 25, 7046-7057.	7.0	56
16	Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. <i>Clinical Cancer Research</i> , 2019, 25, 2042-2048.	7.0	77
17	Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. <i>Clinical Cancer Research</i> , 2019, 25, 358-368.	7.0	51
18	Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 4443-4443.	1.4	6

#	ARTICLE	IF	CITATIONS
19	Implication of Biomarker Mutations for Predicting Survival in Patients With Metastatic Lung Cancer to the Spine. <i>Spine</i> , 2018, 43, E1274-E1280.	2.0	7
20	Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. <i>Onc Immunology</i> , 2018, 7, e1434464.	4.6	69
21	A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 3611-3631.	7.0	39
22	Rare Giant Prevertebral Thoracic Myelomeningocele. <i>World Neurosurgery</i> , 2018, 109, 296-297.	1.3	2
23	Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons. <i>Neurosurgical Focus</i> , 2018, 44, E13.	2.3	25
24	Sporadic NF2 Mosaic: Multiple spinal schwannomas presenting with severe, intractable pain following pregnancy. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2017, 10, 142-145.	0.3	0
25	Effect of Immunotherapy Status on Outcomes in Patients With Metastatic Melanoma to the Spine. <i>Spine</i> , 2017, 42, E721-E725.	2.0	11
26	Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 205-211.	4.2	6
27	Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection. <i>Current Opinion in Virology</i> , 2015, 13, 25-32.	5.4	19
28	Editorial: Not everything that matters can be measured and not everything that can be measured matters. <i>Journal of Neurosurgery</i> , 2015, 123, 543-546.	1.6	3
29	Are BiTEs the "missing link" in cancer therapy?. <i>Onc Immunology</i> , 2015, 4, e1008339.	4.6	59
30	EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma. <i>PLoS ONE</i> , 2014, 9, e94281.	2.5	99
31	Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. <i>Onc Immunology</i> , 2014, 3, e944054.	4.6	19
32	Reply. <i>Plastic and Reconstructive Surgery</i> , 2014, 134, 667e-668e.	1.4	3
33	Impact of PhD training on scholarship in a neurosurgical career. <i>Journal of Neurosurgery</i> , 2014, 120, 730-735.	1.6	29
34	EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss. <i>Clinical Cancer Research</i> , 2014, 20, 972-984.	7.0	254
35	Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 189-190.	1.5	94
36	Factors Influencing Fellowship Selection, Career Trajectory, and Academic Productivity among Plastic Surgeons. <i>Plastic and Reconstructive Surgery</i> , 2014, 133, 730-736.	1.4	89

#	ARTICLE	IF	CITATIONS
37	Response. <i>Journal of Neurosurgery</i> , 2014, 120, 728-9.	1.6	0
38	An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 375-386.	3.1	20
39	BLYS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 983-987.	4.2	13
40	Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody. <i>Cancer Immunology Research</i> , 2013, 1, 163-167.	3.4	61
41	Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. <i>Journal of Immunological Methods</i> , 2013, 395, 14-20.	1.4	5
42	Isocitrate dehydrogenase 1: what it means to the neurosurgeon. <i>Journal of Neurosurgery</i> , 2013, 118, 1176-1180.	1.6	20
43	A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. <i>Oncolmmunology</i> , 2013, 2, e23639.	4.6	16
44	Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. <i>Oncolmmunology</i> , 2013, 2, e26757.	4.6	30
45	Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 270-275.	7.1	120
46	Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice. <i>PLoS ONE</i> , 2013, 8, e59082.	2.5	56
47	Rindopepimut. <i>Drugs of the Future</i> , 2013, 38, 147.	0.1	19
48	Inflammatory Pseudotumor of the Lateral Ventricle in a Pediatric Patient. <i>Pediatric Neurosurgery</i> , 2012, 48, 374-378.	0.7	1
49	Regulatory T Cells Move in When Gliomas Say "el DO". <i>Clinical Cancer Research</i> , 2012, 18, 6086-6088.	7.0	11
50	Enzyme redesign guided by cancer-derived IDH1 mutations. <i>Nature Chemical Biology</i> , 2012, 8, 887-889.	8.0	22
51	Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas. <i>Current Drug Discovery Technologies</i> , 2012, 9, 237-255.	1.2	4
52	Convection Enhanced Delivery of Macromolecules for Brain Tumors. <i>Current Drug Discovery Technologies</i> , 2012, 9, 305-310.	1.2	29
53	Bispecific antibodies engage T cells for antitumor immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 843-853.	3.1	78
54	Imaging of Convection Enhanced Delivery of Toxins in Humans. <i>Toxins</i> , 2011, 3, 201-206.	3.4	20

#	ARTICLE	IF	CITATIONS
55	EGFRvIII-targeted Vaccination Therapy of Malignant Glioma. Brain Pathology, 2009, 19, 713-723.	4.1	118